SCHEMBL22874871

SCHEMBL22874871

CC(C)C1CCN(S(=O)(=O)CC(C)(C)C)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.37
ALDH1A1 P00352 3/20 0.37
GAA P10253 1/20 0.37
EPHX2 P34913 1/20 0.36
LMNA P02545 4/20 0.36
L3MBTL1 Q9Y468 3/20 0.36
TP53 P04637 1/20 0.36
POLB P06746 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
KDM4E B2RXH2 1/20 0.35
TSHR P16473 2/20 0.34
CYP3A4 P08684 1/20 0.34
MAPK1 P28482 1/20 0.34
KMT2A Q03164 2/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
MEN1 O00255 1/20 0.33
LIPE Q05469 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
PKM P14618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15722360 0.86 L3MBTL1 (0.44) MAPTALDH1A1GAAEPHX2LMNA
SCHEMBL12384613 0.79 ALDH1A1 (0.50) MAPTALDH1A1GAALMNAL3MBTL1
SCHEMBL22874873 0.77 ALDH1A1 (0.31) ALDH1A1
SCHEMBL12384513 0.76 ALDH1A1 (0.42) MAPTALDH1A1GAAEPHX2LMNA
SCHEMBL12125449 0.76 ALDH1A1 (0.42) MAPTALDH1A1GAALMNAL3MBTL1
SCHEMBL25926956 0.76 GAA (0.38) ALDH1A1GAAEPHX2LMNAL3MBTL1
SCHEMBL11989586 0.76 L3MBTL1 (0.40) MAPTALDH1A1GAAEPHX2LMNA
SCHEMBL10232861 0.75 L3MBTL1 (0.38) MAPTALDH1A1GAAEPHX2LMNA
SCHEMBL4096090 0.74 CA1 (0.42) MAPTALDH1A1EPHX2SMN1; SMN2
SCHEMBL824151 0.74 TP53 (0.46) MAPTALDH1A1GAALMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11753397-B2 Cereblon binders for the degradation of ikaros C4 THERAPEUTICS, INC. (US) 2023-09-12 US disclosed
US-11753397-B2 Cereblon binders for the degradation of ikaros C4 THERAPEUTICS, INC. (US) 2023-09-12 US disclosed
US-20210009559-A1 CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS C4 THERAPEUTICS, INC. (US) 2021-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11753397-B2 Cereblon binders for the degradation of ikaros CRBN, IKZF1, IKZF3 MAPT 2471/4885ALDH1A1 3363/4885GAA 1798/4885
US-20210009559-A1 CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS CRBN, IKZF1, IKZF3 MAPT 2456/4885ALDH1A1 4009/4885GAA 2106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.